What Is NAD+ and What Does It Do in the Body?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found naturally in almost every cell. It is not a stimulant that supplies ready-made energy. Instead, it participates in reactions that convert energy from food into forms a cell can use. NAD+ is also consumed by enzymes involved in DNA repair, cellular stress responses, immune functions and multiple signalling pathways [1, 12]. The body makes and recycles it from compounds that include vitamin B3 and tryptophan, maintaining distinct pools in different parts of the cell [1, 12].
NAD+ concentrations can vary with age, disease and the tissue being measured. Cell, tissue and animal research describes age-related decline, but human NAD+ measurement is not a routine diagnostic test with one threshold defining an “NAD+ deficiency” [1]. In a community study using whole blood, the relationship with age differed between men and women and was not a uniform decline across every group [2]. The statement that NAD+ may decline with age explains scientific interest, but it does not diagnose an individual or prove that everyone needs an infusion [1, 2].
The key distinction is between mechanism and outcome. NAD+ being essential to cellular life is established biology, but increasing an NAD-related biomarker does not by itself prove better energy, memory, weight or healthspan. Demonstrating benefit requires trials that measure outcomes meaningful to people, not only the concentration of a substance in blood [3, 4].
IV, Injections and Capsules: Are They the Same?
The popular label “NAD+” can conceal very different routes. An IV infusion places NAD+ into the circulation. Subcutaneous or intramuscular injection is another route, but human outcomes research is extremely limited. Capsules usually contain a precursor the body uses to make NAD+, such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), rather than an oral copy of the infusion [1, 4, 12]. Different routes involve different absorption, metabolism and risks, so the result of an oral precursor study cannot simply be transferred to an IV product [3, 4].
The most relevant direct human IV NAD+ study was a small exploratory pilot that tracked the compound and its metabolites in plasma and urine during and after an extended infusion. NAD+ was rapidly removed from plasma initially, followed later by changes in some metabolites and urinary excretion [3]. This helps describe biological handling, but the study was not an efficacy trial for fatigue, concentration or ageing. It does not establish whether an infusion provides a patient-important benefit over capsules [3, 4].
A recent systematic review of NAD-related interventions found that most human trials evaluated oral NR or NMN and that these products often increased NAD-related biomarkers in blood or cells. It found no eligible clinical-outcomes trial of IV or intramuscular NAD+ itself establishing an anti-ageing or general-wellness benefit [4]. “Direct to the bloodstream” therefore describes delivery only. It does not prove superiority, intact delivery to every tissue or a stronger clinical result [3, 4].
What Do Human Trials Actually Establish?
In a small randomized crossover trial of healthy middle-aged and older adults, oral NR increased markers of NAD+ metabolism and was tolerated during the study. Signals involving blood pressure and arterial function were exploratory and require larger trials [5]. A small trial in postmenopausal women with overweight or obesity and prediabetes found improved muscle insulin sensitivity with NMN, without matching improvement in every whole-body or body-composition measure [7]. These are specific findings in selected groups, not general proof of more energy or youth and not evidence for IV NAD+ [5, 7].
When a systematic review and meta-analysis pooled published randomized NMN trials, it found no clear short-term benefit across fasting glucose, insulin, glycated haemoglobin, insulin resistance or lipid outcomes [6]. A broader 2026 systematic review concluded that NR and NMN show clear biological activity, while human functional, metabolic and vascular outcomes were heterogeneous and often null or limited to a particular endpoint [4]. A biomarker change is therefore a research finding, not a promised result.
Earlier reviews combined studies of NADH and NAD precursors across very different populations, including chronic fatigue, older adults and metabolic or neurological conditions. The compounds, conditions and measured outcomes varied too much to turn scattered signals into a fixed list of benefits for an NAD+ infusion [8]. The most accurate current summary is that biological plausibility and preliminary findings exist, but IV NAD+ effectiveness in healthy people remains unproven, while long-term safety and clinically meaningful outcomes need stronger research [4, 8].
What Is Not Proven: Anti-Ageing, Weight Loss and Detox
No robust human trial has yet shown that an NAD+ infusion slows ageing, extends life, prevents an age-related disease or consistently improves memory and energy in healthy people [4]. Animal work helps researchers understand pathways but does not guarantee the same outcome in humans. “Cellular energy” describes biochemical function; it is not a promise that a person will feel an immediate or sustained energy boost after an infusion [1, 4].
IV NAD+ is also not an established weight-loss or belly-fat treatment. A meta-analysis of NMN trials did not show consistent metabolic benefit across major markers, while the broader systematic review described heterogeneous human outcomes [4, 6]. Any weight change must be interpreted in the context of food, activity, sleep, medicines and health conditions rather than automatically attributed to an infusion. “Detox” is medically vague: the liver, kidneys, lungs and digestive system continually process waste, and an NAD+ infusion has not been shown to clear undefined toxins or undo the effects of poor sleep or travel [4, 8].
There is no proven women-specific benefit either. A blood study found sex differences in the association between NAD+ and age, while an NMN trial in women with prediabetes produced a specific metabolic finding; neither establishes general benefits for skin, fertility, hormones or anti-ageing in women [2, 7]. The same evidence rule applies to searches for the “best type”: no route has been established as best for every purpose. A sensible choice starts with a defined medical reason, evidence for the desired outcome, product quality and comparison with simpler alternatives [3, 4].
Side Effects and Sterile-Preparation Risks
Evidence about symptoms during IV NAD+ remains limited, but it is not absent. A very small retrospective real-world study recorded nausea, vomiting, abdominal cramping, diarrhoea, increased heart rate and chest pressure during infusion in its NAD+ group, with symptoms resolving after administration ended [11]. Its size and design cannot estimate risk for everyone, but it confirms that the infusion is not symptom-free. An earlier exploratory study observed no notable events during its extended slow protocol, illustrating why divergent small studies cannot establish comprehensive safety or an ideal administration rate [3, 11].
Every IV procedure also carries cannula and preparation risks: pain or bruising, phlebitis, fluid leaking into tissue, infection and a reaction to a component. The US Food and Drug Administration warned against using food-grade NAD+ to compound sterile drugs after receiving reports of severe chills, shaking, vomiting and fatigue; the reactions were consistent with bacterial endotoxin exposure [10]. Sterile preparation, ingredient source, complete labelling and storage are not administrative details. They are central safety controls [10].
If chest pressure or pain, shortness of breath, wheezing, swelling of the face or tongue, fainting, confusion, severe shaking or persistent vomiting develops during an infusion, administration should stop and immediate medical assessment is needed; some presentations require emergency care according to severity. Even a milder headache or nausea should be reported rather than endured as proof that the treatment is “working.” A qualified observer and a plan for allergy or unstable vital signs are essential safety measures, but supervision does not turn an unproven benefit into a proven one [10, 11].
Who Needs Medical Review First?
Pregnancy and breastfeeding are populations for which adequate data on IV NAD+ or supplement-level precursors are lacking. A pregnant or breastfeeding person should therefore not start an experimental wellness intervention without agreement from the relevant maternity or lactation team. People with heart or kidney disease need assessment before any IV fluid because fluid volume, blood pressure, electrolytes and accompanying medicines matter. Those with liver disease need review because pharmacological forms of vitamin B3 can affect the liver and because NR or NMN findings cannot guarantee the safety of an injectable formulation [4, 12].
With active cancer, the concern is theoretical and complex. Healthy cells and cancer cells both use NAD pathways, and researchers investigate both inhibiting and increasing parts of this metabolism in different contexts [1, 9]. No trial proves that an NAD+ infusion causes or accelerates cancer, but there are also insufficient data establishing that it is safe as a wellness intervention during active cancer treatment. The decision belongs with the oncology team, without presenting the infusion as cell protection or adjunctive cancer therapy [4, 9].
Ask first as well if you have previously reacted to an infusion or injection, have severely unstable blood pressure, an unstable chronic illness, or take multiple medicines and supplements. There is no fixed “NAD test package” for everyone. A clinician should review the reason for considering treatment, symptoms, medical history, medicines, blood pressure and whether kidney, liver, glucose, blood-count or nutrient-deficiency tests are actually indicated. Targeted assessment is more useful than random testing or an experimental infusion that delays identification of a treatable cause [4, 10, 12].
Before Deciding: Start with the Symptom, Not the Infusion Name
If your goal is to treat fatigue or poor concentration, start by describing the problem. When did it begin? Is there inadequate sleep, snoring, low mood, palpitations, weight loss, thirst, breathlessness or a medicine effect? Read our guide to persistent fatigue and which tests to start with to understand why investigations follow the history and examination rather than testing everything at once. Anaemia, thyroid dysfunction, diabetes, selected nutrient deficiencies, sleep disorders and cardiac or psychological causes require different assessments and treatments; an NAD+ infusion diagnoses none of them [4, 8].
If vitamin D is the specific concern, read whether vitamin D deficiency causes fatigue before attributing every symptom to one result. Treating a documented deficiency differs from giving an experimental infusion without a diagnosis. If you still discuss NAD+ after assessment, ask for a measurable goal, the evidence supporting the proposed route, every ingredient in the bag, the source of sterile preparation, who will monitor you and the response plan for symptoms. Do not stop a prescribed medicine or replace it with an infusion [4, 10].
The medical team at La Rose can assess whether this option fits after reviewing your health and any indicated tests, and offers it only after assessment. Its availability as an option does not make it necessary for everyone or establish anti-ageing or weight-loss benefit. If you want to start with a review of fatigue, medicines, nutrition and individual risks, you can book a consultation with the medical team at La Rose. A sound decision may be to treat a defined cause, choose a simpler alternative, defer the infusion or not use it at all [4, 10, 12].
